Dilip Shanghvi net worth
Current Net Worth – $26 Billion (USD – 2,171 Crores), (Rupees – 2.17 Lakh Crores)
Dilip Shanghvi short biography
| Net Worth | $26 Billion |
|---|---|
| Born | October 1, 1955 (Age – 68) |
| Identified as | Founder & Managing Director of Sun Pharmaceuticals |
| Status | One of the country’s richest people & Indian billionaire businessman |
| Education | Bhawanipur Education Society College, the University of Calcutta (Bachelor of Commerce) |
| Nationality | Indian |
| Residence | Mumbai, India |
| Spousal status | Married |
| Wife | Vibha Shanghvi |
| Children | 2 children (Son – Aalok & Daughter – Vidhi) |
Dilip Shanghvi has a net worth of $26 Billion (USD – 2,171 Crores), (Rupees – 2.17 Lakh Crores), making him one of the richest men in India.
He is the founder of Sun Pharmaceuticals a generic drugmaker and an Indian multinational pharmaceutical company.
The Mumbai-based corporation serves over 150 countries and is influenced by around 30,000 employees.
It had made earnings of $4.6 billion in the year to March 31, 2020.
He was listed on 8th rank in India’s most powerful people list 2017 by India Today Magazine and now he is ranking at #253 position in World’s Billionaires List by Forbes.
Amazing Fact
In 2015, when Mukesh Ambani’s wealth drove below $19.5 billion, Dilip Shanghvi grabbed the title of being India’s richest man with more than $20 billion of net worth.
Dilip Shanghvi biography
| Full Name | Dilip Shanghvi |
| Birthplace | Amreli, Gujarat, India |
| Height | 5.7 feet, 170 cm |
| Weight | 70 Kg |
| Father | Shantilal N. Shanghvi |
| Mother | Kumud S. Shanghvi |
Dilip Shanghvi was born on October 1, 1955, in a Jain family in the small town of Amreli in Gujarat.
His father is known as Shantilal Shanghvi, he ran a pharmaceutical trading company for selling generic and marked medications, and his mother is Kumud Shanghvi.
He was raised by his parents in the Burrabazar area of Calcutta, during his childhood and college life.
Education
Shanghvi received a Bachelor of Commerce degree from the University of Calcutta informally known as Calcutta University (CU).
He is a graduate of J. J. Ajmera High School and Bhawanipur Education Society College, where he did his tutoring and graduation.
Career
Shanghvi had begun his journey by supporting his father in his wholesale generic pharmaceutical business in Kolkata, after some period he was supposed of manufacturing his own medications rather than selling other products for small profits.
In 1982, Shanghvi initiated Sun Pharmaceutical Industries Ltd. at Vapi as a two-man operation, and with one psychiatric drug, Lithosun, to treat bipolar disease, he has primarily invested ₹10,000 in it.
Shanghai’s partner Pradeep Ghosh, still works for Sun Pharmaceutical Industries Ltd.
He also has an interest in Sun Pharma Advanced Research and BioLight a Life Sciences investment company.
In 1997, with the purpose of widening Sun’s reach in the United States, Sun also obtained a loss going American company Caraco Pharma.
After many years, Sun Pharma at long last acquired a 61% stake in Taro an Israel pharmaceutical company, and was assigned to pay for the remaining stake around US$367 million in October 2011.
In 2012, Shanghvi strolled down as CEO and chairman and assigned Israel Makov as new CEO, who was previously the former chief executive officer of Teva Pharmaceuticals; instead, Dilip became managing director.
In April 2014, Sun Pharma decided that it would obtain the highest stack in Ranbaxy for US$3.2 billion, its biggest competitor in the Pharmaceutical industry.
It was the biggest ever possession of Sun Pharma and also considered the biggest acquisition that year in the pharmaceutical industry in Asia.
The same year in March 2015, the deal was closed, it was deemed as a decent deal for his organization as later the company’s stocks displayed a rally and made Shanghvi the world’s richest medication mogul.
In February 2015, Shanghvi acquired a 12% stake in Suzlon Energy, a wind turbine producer for $289 million.
By all of this Sun was considered the biggest drug company in India and ranked in the fifth position to be the largest pharmaceutical company across the world.
The major source of Shangvhi’s wealth is a 55% stake in generic medication-maker Sun Pharmaceutical Industries, which pays him extensively.
In 2017, he was assigned as trustee of the Rhodes Scholarship Program at Oxford University.
In January 2018, Shanghvi was nominated to the Reserve Bank of India’s 21-member central board committee by the Indian government.
He has also been appointed as the Chairman of the Board of Directors at IIT Bombay.
Book on Dilip Shanghvi
In 2019, novelist Soma Das wrote a book titled The Reluctant Billionaire, the primary book in which she has narrated the full biography of Dilip Shanghvi.
It was published by Penguin Random House, in November 2019, the book was specified for Tata Literature Award in one of the Best Business Book.
Private & Early life
He got married to Vibha Shanghvi and the couple has two children, the son, Alok, and a daughter, Vidhi.
Both the siblings work in Sun Pharmaceuticals to grow their family business.
Awards
- In 2016, he was awarded by the Government of India by civilian honor of the Padma Shri.
Discovery:
- 1955 – In Gujarat, India, Dilip Shantilal Shanghvi is born.
- 1983 – Sun Pharmaceutical Industries is founded in Kolkata.
- 1989 – Sun Pharma starts selling goods in India.
- 1994 – Saw the initial public offering of Sun Pharma.
- 2007 – The fight for control of Taro Pharmaceuticals begins.
- 2010 – Acquires the majority of Taro Pharmaceutical’s shares.
- 2012 – Israel Makov is appointed chairman of Sun Pharma.
- 2014 – Sun Pharma and Ranbaxy reach a $3.2 billion stock purchase agreement.
- 2015 – Replaces Mukesh Ambani as the richest person in India.
- 2016 – Agrees to buy from Novartis in Japan 14 prescription-only products.
Net worth statistics
- March 2011 – $6.1 B
- March 2012 – $7.4 B
- March 2013 – $9.4 B
- March 2014 – $12.8 B
- March 2015 – $20.0 B
- March 2016 – $16.7 B
- March 2017 – $13.7 B
- March 2018 – $12.8 B
- March 2019 – $7.6 B
- April 2020 – $6.1 B
- April 2021 – $10.9 B
- April 2022 – $15.6 B
- April 2023 – $15.6 B
- April 2024 – $26.7 B
Dilip Shanghvi Quote
“Personally, I feel that a company which looks at problems of other companies and learns from their mistakes is a successful one.”
– Dilip shanghvi
